The federal government says health care facilities should stop using Hospira's Symbiq medication infusion pump because its vulnerable to hacking.» Read More
Regeneron CEO Leonard Schleifer talks about an FDA panel's approval of Sanofi-Regeneron's new cholesterol-lowering drugs.
CNBC's Dominic Chu reports summer is on the way but there are a couple of sectors that have gone cold.
Abrar Mir, managing partner at Quadria Capital Fund, says the $300 million raised for healthcare investments in Asia is "a drop in the ocean" compared to the region's growth rate.
CNBC's Meg Tirrell reports on a FDA panel considering whether to approve the first in a new class of drugs many experts believe could cut the risk of heart attacks and strokes.
Ten so-called breakthrough drugs for cancers and chronic conditions will cost taxpayers big bucks.
Reports of a $18-billion bid by Shire for Swiss biotech firm Actelion suggest that the European pharma deal-making flurry is far from over.
CNBC's Meg Tirrell reports on the woman's libido drug.
A drug to treat low female sexual desire should be approved with strict measures to ensure patients are aware of its risks, an FDA panel concluded.
The U.S. Securities and Exchange Commission filed a lawsuit over an alleged fake offer to buy Avon Products.
Teva Pharmaceutical is looking to buy more shares in Mylan, positioning itself for a possible legal challenge to the generics drugmaker.
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.
CNBC's Meg Tirrell speaks with Dr. Richard Pazdur, FDA Cancer Czar, about immunotherapy and drug innovation at the American Society of Clinical Oncology Conference.
Patrick Mahaffy, Clovis Oncology CEO, weighs in on drug prices, business development, and immunotherapy with CNBC's Meg Tirrell.
Michael Yee, RBC Capital Markets biotech analyst, gives perspective to Puma Biotech and other action in the pharmaceutical industry.
Despite disappointing trial results on Friday, the CEO of Bristol-Myers remains optimistic.
Top technician Carter Worth says Apple and biotech look "married." He explains why they are the must-own names in the market right now.
Giovanni Caforio, Bristol-Myers Squibb CEO, joins CNBC's Meg Tirrell to discuss data in lung cancer and the importance of valuable medicines becoming available to patients.
CNBC's Meg Tirrell has the update on the latest development from this year's American Society of Clinical Oncology meeting.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
There have only been four flu pandemics since the start of the 20th century, yet concerns are widening about the potential for a new outbreak.
Get the best of CNBC in your inbox